CD8A and melanoma: Similar results were seen from killing assays using CD8+ T cells from Donors 216T and 192D; MC.7.G5 TCR-replaced CD8+ T cells and the MC.7.G5 T cell clone showed good killing of MR1*01 homozygous melanoma line FM74 at an effector-to-target ratio of 1:1, while CD8+ T cells from both donors transduced with the MC.7.G5 TCR without KO of the endogenous TCR-β chain showed little killing of these cancer targets (Figure 7G).